Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026

Mineralys Therapeutics presented new clinical trial data for lorundrostat, its investigational aldosterone synthase inhibitor for treating difficult-to-treat hypertension. The Launch-HTN trial showed 46% of participants achieved AHA/ACC guideline systolic blood pressure targets (<130 mmHg) at 12 weeks, with over two-thirds achieving ≥10 mmHg reduction. The Explore-OSA trial demonstrated clinically meaningful morning blood pressure reductions in obstructive sleep apnea patients with no adverse effects on sleep apnea indices.